AI-Powered Microbiome Intelligence for Human Health
Alphabiome’s groundbreaking technology extracts genetic biomarkers from microbial DNA at an unprecedented scale and precision to predict the efficacy of biological and biochemical treatments.
Cracking the Genetic Code of the Microbiome
The microbiome holds immense untapped potential for predicting drug efficacy. Alphabiome’s revolutionary AI platform deciphers the previously inaccessible 99% of microbial genetic data with groundbreaking precision, identifying valuable biomarkers at unprecedented scale and unlocking new possibilities for precision medicine.
Discover Alphabiome
Learn more about how Alphabiome’s groundbreaking technology is opening new frontiers in precision medicine.
Alphabiome’s AI-driven proprietary technology deciphers trillions of genetic data fragments to identify biomarkers that will transform drug development by optimizing personalized treatment selection.
With over 100,000 biomarkers discovered, we are unlocking unprecedented opportunities for medical breakthroughs.
Leveraging vast genetic datasets, we empower pharmaceutical companies to predict treatment efficacy with greater accuracy – accelerating personalized medicine and improving patient outcomes.
Our technology seamlessly adapts across a broad spectrum of drugs and treatments, from blockbuster therapies to repurposed phase 2 candidates – driving diverse revenue streams through licensing, accelerated approvals, and targeted innovation.
Scientific Leadership
Founder & CEO
MIT Professor and AI Pioneer
Nobel Laureate in Chemistry
Nobel Laureate in Chemistry
06/05/2025
Alphabiome Unveils Revolutionary AI Technology for Microbiome Decoding
Yahoo Finance- Using proprietary algorithms and advanced modeling, Alphabiome deciphers hidden microbial DNA to accurately predict individual drug response — setting a new standard in personalized medicine.
06/05/2025
AI That Predicts Drug Response — Powered by the Microbiome
Health Technolog Net- Alphabiome’s proprietary platform analyzes microbial DNA beyond reference genomes, delivering unmatched accuracy in forecasting therapeutic outcomes.
07/05/2025
Alphabiome Raises $8M to Scale Microbiome AI
Finsmes.com- Alphabiome secures seed funding to expand R&D and advance its proprietary platform for predicting drug response with greater precision.
